



Memorandum to: Clinical Staff

From: Laboratory & Pharmacy Department

Date: May 14, 2024

Subject: Ceftriaxone Manufacturer Concentration Errors

Due to manufacturer ceftriaxone concentration errors, there is a potential for false susceptible and/or false resistant results on gram-negative isolates. Until this error is remedied, susceptibility results for ceftriaxone will be suppressed from reporting for affected isolates (mostly Enterobacterales).

Cefuroxime results may assist in therapy decision-making. For example, if an isolate is cefuroxime-susceptible, ceftriaxone susceptibility can be presumed. If cefuroxime is resistant but cefepime is susceptible, ceftriaxone should not be presumed susceptible, and definitive ceftriaxone MIC results are required for treatment. Contact the microbiology laboratory within 48 hours to initiate reference lab testing by an alternate method.

Should you have any questions or require further information, please do not hesitate to contact me at mark.berry@iredellhealth.org or Dr. Asha Sigei, at IMH laboratory at ext. 4948.

We will continue to provide updates and adjust practice as we learn more from the company.